We have estimated that the prevalence of pathogenic BRCA1/2 variants in Portuguese patients with metastatic prostate cancer subject to universal testing is 3.1% (95% credibility interval 0.3-10.3%). Here, BRCA1 is linked to metastatic prostate carcinoma.